Prospective evaluation of changes in tumor size and tumor metabolism in patients with advanced gastric cancer undergoing chemotherapy: Association and clinical implication
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park S. | - |
dc.contributor.author | Ha S. | - |
dc.contributor.author | Kwon H.W. | - |
dc.contributor.author | Kim W.H. | - |
dc.contributor.author | Kim T.-Y. | - |
dc.contributor.author | Oh D.-Y. | - |
dc.contributor.author | Cheon G.J. | - |
dc.contributor.author | Bang Y.-J. | - |
dc.date.available | 2020-11-02T10:41:01Z | - |
dc.date.issued | 2017-06 | - |
dc.identifier.issn | 0161-5505 | - |
dc.identifier.issn | 1535-5667 | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/5650 | - |
dc.description.abstract | chemotherapy remains unclear. We aimed to evaluate response of tumor size and metabolism in AGC during chemotherapy and to reveal the relationship between them in view of their impact on patient survival. Methods: We prospectively enrolled patients with AGC before the initiation of first-line palliative chemotherapy. Using baseline and follow-up contrast-enhanced CT and 18F-FDG PET, we assessed the tumor diameter, SUVmax, and total lesion glycolysis in each lesion and their changes during chemotherapy at the same time. We included all lesions with the maximal longest diameters over 1 cm on CT, and each lesion was evaluated by matched 18F-FDG PET. We analyzed the association between changes in tumor metabolism and tumor size and performed outcome analysis on overall survival (OS) and progression-free survival (PFS). Results: Seventy-four patients were enrolled, and the number of all lesions included in this study was 620. Compared with adenocarcinomas, poorly cohesive carcinomas demonstrated lower SUVmax irrespective of tumor size (P , 0.001). Human epidermal growth factor receptor 2 (HER2)-positive tumors showed higher SUVmax than HER2-negative tumors (P 5 0.002). The changes in SUVmax due to chemotherapy had a linear correlation with the changes in tumor size of each lesion, and a 30% tumor size reduction was associated with a 50% SUVmax reduction (P , 0.001). Total lesion glycolysis changes also correlated with tumor size changes (P , 0.001). Better OS and PFS were obtained in patients with both tumor size and SUVmax reduction than in patients with either size or SUVmax reduction only (OS, P 5 0.003; PFS, P 5 0.038). Conclusion: Changes in tumor metabolism induced by chemotherapy correlated with changes in tumor size in AGC. Considering both changes in metabolism and size could help predict a more accurate prognosis for AGC patients undergoing chemotherapy. © 2017 by the Society of Nuclear Medicine and Molecular Imaging. | - |
dc.format.extent | 6 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Society of Nuclear Medicine Inc. | - |
dc.title | Prospective evaluation of changes in tumor size and tumor metabolism in patients with advanced gastric cancer undergoing chemotherapy: Association and clinical implication | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.2967/jnumed.116.182675 | - |
dc.identifier.scopusid | 2-s2.0-85020218680 | - |
dc.identifier.wosid | 000402572500013 | - |
dc.identifier.bibliographicCitation | Journal of Nuclear Medicine, v.58, no.6, pp 899 - 904 | - |
dc.citation.title | Journal of Nuclear Medicine | - |
dc.citation.volume | 58 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 899 | - |
dc.citation.endPage | 904 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Radiology, Nuclear Medicine & Medical Imaging | - |
dc.relation.journalWebOfScienceCategory | Radiology, Nuclear Medicine & Medical Imaging | - |
dc.subject.keywordPlus | capecitabine | - |
dc.subject.keywordPlus | cisplatin | - |
dc.subject.keywordPlus | epidermal growth factor receptor 2 | - |
dc.subject.keywordPlus | fluorodeoxyglucose f 18 | - |
dc.subject.keywordPlus | fluorouracil | - |
dc.subject.keywordPlus | folinic acid | - |
dc.subject.keywordPlus | irinotecan | - |
dc.subject.keywordPlus | oxaliplatin | - |
dc.subject.keywordPlus | trastuzumab | - |
dc.subject.keywordPlus | antineoplastic agent | - |
dc.subject.keywordPlus | fluorodeoxyglucose f 18 | - |
dc.subject.keywordPlus | radiopharmaceutical agent | - |
dc.subject.keywordPlus | adult | - |
dc.subject.keywordPlus | advanced cancer | - |
dc.subject.keywordPlus | aged | - |
dc.subject.keywordPlus | cancer chemotherapy | - |
dc.subject.keywordPlus | cancer palliative therapy | - |
dc.subject.keywordPlus | cancer prognosis | - |
dc.subject.keywordPlus | clinical feature | - |
dc.subject.keywordPlus | cohort analysis | - |
dc.subject.keywordPlus | Conference Paper | - |
dc.subject.keywordPlus | contrast enhancement | - |
dc.subject.keywordPlus | correlational study | - |
dc.subject.keywordPlus | disease association | - |
dc.subject.keywordPlus | drug response | - |
dc.subject.keywordPlus | female | - |
dc.subject.keywordPlus | follow up | - |
dc.subject.keywordPlus | glycolysis | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | major clinical study | - |
dc.subject.keywordPlus | male | - |
dc.subject.keywordPlus | metabolism parameters | - |
dc.subject.keywordPlus | multiple cycle treatment | - |
dc.subject.keywordPlus | overall survival | - |
dc.subject.keywordPlus | PET-CT scanner | - |
dc.subject.keywordPlus | positron emission tomography-computed tomography | - |
dc.subject.keywordPlus | priority journal | - |
dc.subject.keywordPlus | progression free survival | - |
dc.subject.keywordPlus | prospective study | - |
dc.subject.keywordPlus | stomach adenocarcinoma | - |
dc.subject.keywordPlus | stomach cancer | - |
dc.subject.keywordPlus | tumor volume | - |
dc.subject.keywordPlus | clinical trial | - |
dc.subject.keywordPlus | disease free survival | - |
dc.subject.keywordPlus | drug effects | - |
dc.subject.keywordPlus | metabolic clearance rate | - |
dc.subject.keywordPlus | metabolism | - |
dc.subject.keywordPlus | middle aged | - |
dc.subject.keywordPlus | pathology | - |
dc.subject.keywordPlus | procedures | - |
dc.subject.keywordPlus | prognosis | - |
dc.subject.keywordPlus | reproducibility | - |
dc.subject.keywordPlus | sensitivity and specificity | - |
dc.subject.keywordPlus | Stomach Neoplasms | - |
dc.subject.keywordPlus | survival rate | - |
dc.subject.keywordPlus | tumor volume | - |
dc.subject.keywordPlus | very elderly | - |
dc.subject.keywordPlus | Adult | - |
dc.subject.keywordPlus | Aged | - |
dc.subject.keywordPlus | Aged, 80 and over | - |
dc.subject.keywordPlus | Antineoplastic Agents | - |
dc.subject.keywordPlus | Disease-Free Survival | - |
dc.subject.keywordPlus | Female | - |
dc.subject.keywordPlus | Fluorodeoxyglucose F18 | - |
dc.subject.keywordPlus | Glycolysis | - |
dc.subject.keywordPlus | Humans | - |
dc.subject.keywordPlus | Male | - |
dc.subject.keywordPlus | Metabolic Clearance Rate | - |
dc.subject.keywordPlus | Middle Aged | - |
dc.subject.keywordPlus | Positron Emission Tomography Computed Tomography | - |
dc.subject.keywordPlus | Prognosis | - |
dc.subject.keywordPlus | Prospective Studies | - |
dc.subject.keywordPlus | Radiopharmaceuticals | - |
dc.subject.keywordPlus | Reproducibility of Results | - |
dc.subject.keywordPlus | Sensitivity and Specificity | - |
dc.subject.keywordPlus | Stomach Neoplasms | - |
dc.subject.keywordPlus | Survival Rate | - |
dc.subject.keywordPlus | Tumor Burden | - |
dc.subject.keywordAuthor | Chemotherapy | - |
dc.subject.keywordAuthor | Metabolism | - |
dc.subject.keywordAuthor | Positron-emission tomography | - |
dc.subject.keywordAuthor | Prognosis | - |
dc.subject.keywordAuthor | Stomach neoplasm | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.